Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this module, Lee R Goldberg, MD, MPH, and James Udelson MD, discuss key studies that will affect the management of patients with heart failure (HF), including new data on sodium-glucose cotransporter 2 (SGLT2) inhibition in HF, and treatments for HF with reduced ejection fraction and HF with preserved ejection fraction.